Corcept Therapeutics Faces Securities Class Action: What Investors Need to Know

Overview of the Corcept Litigation

Introduction

Corcept Therapeutics, Inc. (NASDAQ: CORT) is currently embroiled in a significant legal battle that is raising concerns among investors. A securities class action lawsuit has been initiated by the renowned law firm Hagens Berman, targeting the company and its executive team. The lawsuit aims to recover losses incurred by investors who purchased Corcept stock between October 31, 2024, and December 30, 2025, during a time where the company's assurances regarding its lead product were sharply at odds with growing regulatory scrutiny.

Background

The legal action stems from allegations that Corcept made misleading claims regarding the readiness of its lead product candidate, relacorilant, for regulatory approval. According to the complaint, while Corcept was promoting the drug as being supported by "powerful evidence" and "approaching approval," they allegedly ignored multiple warnings from the FDA regarding the inadequacy of their clinical data. This is believed to have contributed to a drastic drop in the company’s stock price, which plunged nearly 50% following the receipt of a Complete Response Letter (CRL) from the FDA on December 31, 2025.

Allegations Against Corcept

The crux of the lawsuit lies in the assertion that Corcept misrepresented information related to its regulatory submissions for relacorilant. Key allegations include:

- Concealed FDA Concerns:

During pre-submission meetings, the FDA reportedly indicated significant concerns about the adequacy of Corcept's clinical development program, which the company failed to disclose to its investors. By not sharing these warnings, Corcept is accused of creating a false narrative concerning the viability of relacorilant and its chances for FDA approval.

- Warning to Not File:

Evidence within the complaint reveals that the FDA cautioned Corcept. It indicated that submitting the New Drug Application (NDA) without necessary additional evidence might lead to rejection. This critical information was allegedly withheld from shareholders, further deepening the claims against the company.

- Market Impact:

The saga took a severe turn when, after the issuance of the CRL, shares of Corcept plummeted from $70.20 to $34.80 in just one day. This drastic decrease wiped out over $3.6 billion in market capitalization, leaving investors with significant financial losses.

Key Dates and Next Steps for Investors

Investors who acquired Corcept stock during the defined class period should be aware of important deadlines. Specifically, April 21, 2026, is highlighted as a critical date for individuals wanting to take action in this case. Those interested in potentially becoming Lead Plaintiffs are encouraged to contact Hagens Berman. The firm is urging all other investors who suffered notable losses to reach out and explore their options within this lawsuit.

Conclusion

As the legal proceedings develop, it remains essential for investors to stay informed about the implications of this class action lawsuit against Corcept Therapeutics. The allegations present significant concerns regarding corporate governance and investor rights in the biotech sector. As the investigation by Hagens Berman unfolds, stakeholders will be watching closely to see how these issues will be addressed and what outcomes may emerge for those affected by these substantial losses. Investors are encouraged to visit the Hagens Berman CORT Case Page for further updates and relevant information about the ongoing situation.

Contact Information

For those who have sustained substantial losses or possess information pertinent to the investigation, they can contact Hagens Berman partner Reed Kathrein at 844-916-0895 or via email. Additionally, individuals with non-public information regarding Corcept are encouraged to explore the SEC Whistleblower program, potentially available for those providing crucial data for the lawsuit's resolution.

About Hagens Berman

Hagens Berman is a global plaintiffs' rights law firm committed to corporate accountability. The firm has a rich history of representing investors, consumers, and whistleblowers, securing significant outcomes in complex litigation. With a history of driving over $2.9 billion for clients, Hagens Berman continues to be a key player in championing corporate transparency and accountability in the face of wrongdoing.